ReNeuron is focused on human retinal progenitor cell therapy (hRPC) for retinitis pigmentosa (RP). Ongoing Phase IIa data show a stable average gain in visual acuity. A nine-patient continuation Phase IIa study is underway at a higher dose. A placing of £15m and an open offer of up to £2.5m at 70p/share, totalling up to £17.5m before costs, are planned to give at least 18 months cash to complete the Phase IIa, potentially initiate a pivotal study in H2 CY22 and progress preclinical exosome and o ....
08 Dec 2020
ReNeuron Group - Funding to complete Phase IIa and other projects
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
ReNeuron Group - Funding to complete Phase IIa and other projects
ReNeuron Group plc (RENE:LON) | 3.0 0 0.0% | Mkt Cap: 1.74m
- Published:
08 Dec 2020 -
Author:
Dr John Savin -
Pages:
3
ReNeuron is focused on human retinal progenitor cell therapy (hRPC) for retinitis pigmentosa (RP). Ongoing Phase IIa data show a stable average gain in visual acuity. A nine-patient continuation Phase IIa study is underway at a higher dose. A placing of £15m and an open offer of up to £2.5m at 70p/share, totalling up to £17.5m before costs, are planned to give at least 18 months cash to complete the Phase IIa, potentially initiate a pivotal study in H2 CY22 and progress preclinical exosome and o ....